Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company have made the US Food and Drug Administration (FDA) approved Tradjenta (linagliptin) tablets available at pharmacies across the US.
Subscribe to our email newsletter
Earlier this year, Boehringer Ingelheim and Lilly collaborated in the field of diabetes that centers on four pipeline compounds representing several of the largest treatment classes.
Tradjenta, which belongs to a class of prescription medications called dipeptidyl peptidase-4 (DPP-4) inhibitors, is a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Tradjenta was approved based on a clinical trial program that included approximately 4,000 adults with type 2 diabetes.
Tradjenta showed statistically significant hemoglobin A1C reductions of up to 0.7% when used as monotherapy (compared to placebo).
When used in combination with metformin, sulfonylurea, and metformin plus sulfonylurea, the addition of Tradjenta resulted in significant hemoglobin A1C reductions of 0.6, 0.5, and 0.6% respectively (compared to placebo).
In the initial combination of Tradjenta plus pioglitazone, significant reductions in hemoglobin A1C of 0.5% were observed compared to placebo.